LOS ANGELES, CA – In a significant stride against one of the most aggressive and intractable forms of cancer, researchers at Keck Medicine of USC have unveiled a groundbreaking combination therapy that shows unprecedented promise for glioblastoma, a devastating brain tumor diagnosis notoriously resistant to conventional treatments. This innovative approach, combining Tumor Treating Fields (TTFields) therapy with immunotherapy (pembrolizumab) and chemotherapy (temozolomide), significantly extended the lives of patients in a recent study, offering a beacon of hope where few effective options have historically existed.
Glioblastoma, a highly malignant brain tumor, carries a grim prognosis, with the National Brain Tumor Society reporting an average patient survival of just eight months. The scarcity of effective treatments underscores the urgent need for therapeutic breakthroughs, a need that the findings from Keck Medicine of USC are poised to address. The study suggests that this novel three-pronged attack not only disrupts tumor growth but also strategically primes the body’s immune system to launch a sustained assault on the cancer, potentially redefining the treatment landscape for this deadly disease.
A Relentless Foe: The Challenge of Glioblastoma
Glioblastoma multiforme (GBM) stands as the most common and aggressive primary malignant brain tumor in adults. Its inherent complexity and relentless progression pose immense challenges for patients and clinicians alike. Characterized by rapid, infiltrative growth, GBM often defies complete surgical resection and exhibits profound resistance to standard therapies, including radiation and chemotherapy. The tumor’s insidious nature, coupled with its location within the central nervous system, creates a uniquely hostile environment for treatment. The blood-brain barrier, a natural protective mechanism, inadvertently becomes an obstacle, shielding the tumor from many therapeutic agents, including components of the body’s own immune system.
Historically, the standard of care for newly diagnosed glioblastoma involves maximal safe surgical resection, followed by concurrent radiation therapy and temozolomide chemotherapy. While this aggressive protocol can offer temporary control, recurrence is almost inevitable, and the median overall survival has remained stubbornly low for decades. Immunotherapy, a revolutionary treatment for many other cancers, has largely proven ineffective against glioblastoma when used as a standalone treatment, a testament to the tumor’s sophisticated immunosuppressive strategies and the formidable challenge of penetrating the brain’s unique microenvironment. The sheer despair associated with a glioblastoma diagnosis underscores why any significant advancement, particularly one demonstrating improved survival, is met with profound anticipation.
Unveiling the Triple-Threat Strategy: A New Therapeutic Paradigm
The Keck Medicine of USC study introduces a novel combination therapy designed to overcome glioblastoma’s formidable defenses. At its core are three distinct modalities: Tumor Treating Fields (TTFields) therapy, the immune checkpoint inhibitor pembrolizumab (immunotherapy), and the alkylating agent temozolomide (chemotherapy). Each component plays a critical, synergistic role in this multifaceted assault on the tumor.
Tumor Treating Fields (TTFields): Disrupting Growth, Inviting the Immune System
TTFields therapy represents a cutting-edge approach that delivers targeted, low-intensity alternating electric fields directly into tumors. This non-invasive, locoregional treatment is designed to disrupt the rapid division of cancer cells without significantly harming healthy cells. The mechanism of action is elegant yet powerful: the electric fields push and pull key intracellular structures, such as microtubules (which are vital for cell division), in continually shifting directions. This constant mechanical interference makes it exceedingly difficult for tumor cells to complete mitosis, effectively halting their proliferation and inducing cell death.
For glioblastoma patients, TTFields are delivered via a set of mesh electrodes strategically positioned on the scalp. These electrodes generate electric fields at a precise frequency and intensity, meticulously focused on the tumor’s location. Patients typically wear these electrodes for approximately 18 hours a day, allowing for continuous disruption of cancerous cell cycles. Beyond its direct anti-proliferative effects, TTFields therapy has another crucial function: it signals the body’s immune system. Researchers observed that TTFields attract a greater number of tumor-fighting T cells—specialized white blood cells capable of identifying and destroying cancer cells—into and around the glioblastoma, effectively preparing the battlefield for subsequent immune intervention.
Pembrolizumab: Unleashing the Body’s Own Defenders
Pembrolizumab is an immune checkpoint inhibitor (ICI) that acts by blocking the PD-1 protein on T cells. This protein, when engaged by its ligand PD-L1 (often found on cancer cells), acts as an "off switch" that prevents T cells from attacking tumor cells. By blocking PD-1, pembrolizumab removes this inhibitory brake, thereby enhancing the T cells’ ability to identify, activate, and mount a robust immune response against cancer. This form of immunotherapy has revolutionized the treatment of numerous cancers, but its efficacy in glioblastoma has been severely limited.
The primary hurdle for immunotherapy in glioblastoma has been the extremely immunosuppressive microenvironment within the brain tumor and the formidable blood-brain barrier. This barrier, essential for protecting the brain from harmful substances, also restricts the infiltration of immune cells, including T cells, and many therapeutic agents. Consequently, glioblastomas typically contain very few T cells, rendering even powerful ICIs like pembrolizumab largely ineffective when administered alone. The lack of sufficient "players" (T cells) within the tumor has historically prevented immunotherapy from gaining traction in glioblastoma.
Temozolomide: The Standard Bearer
Temozolomide is an oral alkylating chemotherapy agent that has been the cornerstone of glioblastoma treatment for nearly two decades. It works by damaging the DNA of cancer cells, leading to their death. While effective in conjunction with radiation, temozolomide alone has limited efficacy against recurrent glioblastoma, and its impact on overall survival, while significant when first introduced, remains modest compared to the aggressive nature of the disease. In this new combination, temozolomide serves as a foundational chemotherapy, working alongside TTFields and immunotherapy to maximize the therapeutic impact.
The Synergistic Breakthrough: Overcoming Glioblastoma’s Defenses
The true brilliance of this new approach lies in the synergistic interplay between TTFields and immunotherapy, with chemotherapy providing a crucial baseline attack. As Dr. David Tran, MD, PhD, chief of neuro-oncology with Keck Medicine, co-director of the USC Brain Tumor Center, and corresponding author of the study, eloquently explains, "By using TTFields with immunotherapy, we prime the body to mount an attack on the cancer, which enables the immunotherapy to have a meaningful effect in ways that it could not before."
Dr. Tran theorized that the most effective way to circumvent the immunosuppressive environment and the blood-brain barrier was to initiate an immune reaction directly within the tumor itself—an approach known as in situ immunization. TTFields appear to be the catalyst for this process. By disrupting tumor cells, TTFields not only directly impede growth but also expose tumor antigens and create a pro-inflammatory environment that actively recruits T cells into the tumor. Once these crucial T cells have infiltrated the glioblastoma, the immune checkpoint inhibitor, pembrolizumab, can then "release the brakes" on these newly arrived and activated T cells. This allows them to stay active longer, proliferate, and become even more effective tumor-fighting agents. The study demonstrates that this combination triggers a potent immune response within the tumor, one that ICIs can then amplify to bolster the body’s own defense against cancer.
"Think of it like a team sport," Dr. Tran, who is also a member of the USC Norris Comprehensive Cancer Center, further elaborated. "Immunotherapy sends players in to attack the tumor (the offense), while TTFields weaken the tumor’s ability to fight back (the defense). And just like in team sports, the best defense is a good offense." This powerful analogy underscores how TTFields create the necessary conditions for immunotherapy to finally succeed where it previously failed, effectively unlocking its value in treating glioblastoma.
Promising Results from the 2-THE-TOP Phase 2 Trial
The encouraging findings emerged from the 2-THE-TOP, a Phase 2 clinical trial that provided the first substantial evidence of this combination therapy’s potential. The trial enrolled 31 newly diagnosed glioblastoma patients who had already completed standard chemoradiation therapy. Of these, 26 patients subsequently received the innovative triple combination of TTFields, chemotherapy, and immunotherapy. A particularly high-risk subgroup within this cohort consisted of seven patients whose tumors were inoperable due to their location, representing individuals with the worst prognosis and very few, if any, treatment alternatives.
Patients in the trial underwent a structured treatment regimen: six to twelve monthly cycles of chemotherapy alongside continuous TTFields therapy for up to 24 months, with the duration adjusted based on individual patient response. The immunotherapy (pembrolizumab) was administered every three weeks, commencing with the second dose of chemotherapy, also for up to 24 months. This meticulous and prolonged treatment schedule was designed to maximize the synergistic effects of the therapies.
A Significant Leap in Survival
The results were remarkable. Patients who received the combination of TTFields, chemotherapy, and immunotherapy experienced a significant improvement in overall survival. Specifically, the study reported a striking 70% increase in overall survival compared to historical data and previous treatments involving TTFields with chemotherapy alone. This translates to patients living approximately 10 months longer, a profound difference in the context of a disease where survival is measured in single-digit months. This substantial extension of life offers not just more time, but potentially a significantly improved quality of life for patients and their families.
The Unexpected Advantage of Larger Tumors
Perhaps one of the most intriguing and counter-intuitive findings of the study was the observation that patients with larger, unresected (not surgically removed) tumors showed an even stronger immune response to TTFields and, consequently, lived even longer—approximately 13 months longer than those who underwent surgical removal of their tumors. This finding challenges conventional wisdom in glioblastoma treatment, which typically prioritizes maximal surgical debulking whenever possible.
The researchers hypothesize that for patients receiving this specific combination therapy, having a larger tumor may provide more targets for the therapy to work against, essentially acting as an "in situ vaccine." The TTFields, by disrupting a greater mass of tumor cells, could potentially expose a larger array of tumor antigens, thereby amplifying the immune system’s recognition and response. This suggests that, when it comes to kick-starting the body’s immune response against the cancer, a more substantial tumor burden might paradoxically offer a greater opportunity for immune activation.
Dr. Tran noted the importance of this finding: "Further studies are needed to determine the optimal role of surgery in this setting, but these findings may offer hope, particularly for glioblastoma patients who do not have surgery as an option." This opens up exciting possibilities for patients whose tumors are deemed inoperable due to size, location, or patient health, who have historically faced the most dire prognoses.
Paving the Way for a New Standard: The Ongoing Phase 3 Trial
Recognizing the immense potential of these Phase 2 results, Keck Medicine of USC is actively participating in a pivotal multicenter Phase 3 clinical trial. This large-scale trial is crucial for validating the efficacy and safety of the TTFields, immunotherapy, and chemotherapy combination, and ultimately, for establishing it as a new standard of care for glioblastoma.
Dr. Tran, whose dedication to researching TTFields spans more than a decade, serves as the distinguished chair of the steering committee for this ambitious Phase 3 trial, highlighting the institution’s leadership in this cutting-edge research. Dr. Frances Chow, a neuro-oncologist with USC Norris, is the principal investigator of the Keck Medicine study site, overseeing the local efforts in this global endeavor.
The Phase 3 trial is currently open at an extensive network of 28 sites across the United States, Europe, and Israel. The trial aims to enroll over 740 patients through April 2029, a testament to the rigorous scientific process required for drug approval and widespread clinical adoption. A key objective of this comprehensive trial is to meticulously assess the extent to which surgically removing tumors influences the immune response. To achieve this, the trial will include patients with varying degrees of surgical intervention—from gross total resection to partial resection or biopsy-only tumors—allowing researchers to precisely determine the optimal treatment strategy in relation to surgical status, especially in light of the surprising Phase 2 findings regarding unresected tumors. This meticulous approach ensures that the eventual recommendations will be robust and tailored to the diverse clinical presentations of glioblastoma.
The Road Ahead: Hope on the Horizon
The findings from Keck Medicine of USC represent more than just a scientific discovery; they embody a profound shift in the battle against glioblastoma. For decades, patients and their families have navigated a landscape defined by limited options and often devastating outcomes. This new combination therapy offers a tangible and significant extension of life, along with the promise of a more effective and durable response to treatment.
The potential for TTFields to "unlock" the power of immunotherapy in glioblastoma is a game-changer, demonstrating that even the most formidable cancers can be made vulnerable through intelligent, synergistic therapeutic design. As the Phase 3 trial progresses, the global medical community watches with bated breath, hopeful that this innovative approach will soon translate into a new era of hope and improved survival for glioblastoma patients worldwide. The work by Dr. Tran and his team exemplifies the relentless pursuit of solutions against seemingly insurmountable diseases, reinforcing the critical importance of translational research in bringing life-changing treatments from the lab to the clinic.
Research Team and Funding Acknowledgements
The groundbreaking study at Keck School of Medicine of USC included a dedicated team of authors: Dongjiang Chen, PhD, assistant professor of research neurological surgery; Son Le, PhD, assistant professor of research neurological surgery; Harshit Manektalia, research programmer; Ming Li, PhD, professor of research population and public health sciences; and Adam O’Dell, research lab specialist. Collaborating colleagues from the University of Florida, Ashley Ghiaseddin, MD, and Maryam Rahman, MD, MS, also made significant contributions to this important work.
This vital research was made possible through funding provided by a grant from Novocure, the manufacturer of Optune, the TTFields device utilized in this study. It is also noted that Dr. Tran has received honoraria from Novocure for consultant work, and both Dr. Chen and Dr. Tran are inventors on two patent applications related to the work reported in this study, underscoring the innovative nature and potential impact of their discoveries.
About the Author
